Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lessened its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 40.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,263 shares of the company's stock after selling 16,683 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in Amphastar Pharmaceuticals were worth $1,177,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its holdings in Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $32,000 after purchasing an additional 273 shares during the last quarter. Innealta Capital LLC acquired a new position in Amphastar Pharmaceuticals in the second quarter valued at approximately $55,000. Blue Trust Inc. grew its position in Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after acquiring an additional 309 shares during the period. nVerses Capital LLC increased its position in shares of Amphastar Pharmaceuticals by 37.5% during the 2nd quarter. nVerses Capital LLC now owns 2,200 shares of the company's stock worth $88,000 after purchasing an additional 600 shares during the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at about $93,000. Hedge funds and other institutional investors own 65.09% of the company's stock.

Analyst Ratings Changes

Several research firms have recently commented on AMPH. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. StockNews.com lowered shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $63.00.

Insider Activity

In other news, Director Floyd F. Petersen sold 3,000 shares of the firm's stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the sale, the director now owns 75,409 shares of the company's stock, valued at approximately $3,504,256.23. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Floyd F. Petersen sold 3,000 shares of the business's stock in a transaction on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares of the company's stock, valued at $3,504,256.23. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard K. Prins sold 17,101 shares of the company's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the transaction, the director now owns 33,971 shares of the company's stock, valued at $1,463,130.97. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,101 shares of company stock worth $1,069,350. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Stock Up 0.4 %

AMPH stock traded up $0.20 during mid-day trading on Friday, reaching $50.73. The company had a trading volume of 181,198 shares, compared to its average volume of 391,857. The firm has a fifty day simple moving average of $48.24 and a 200 day simple moving average of $43.77. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 0.97 and a beta of 0.83. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a net margin of 23.36% and a return on equity of 29.79%. The firm had revenue of $182.39 million for the quarter, compared to analysts' expectations of $171.29 million. Analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.7 earnings per share for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.